{"id":29903,"date":"2025-01-07T10:18:29","date_gmt":"2025-01-07T09:18:29","guid":{"rendered":"https:\/\/ggba.swiss\/?p=29903"},"modified":"2025-01-08T14:06:51","modified_gmt":"2025-01-08T13:06:51","slug":"vandria-begins-clinical-trials-for-alzheimers-drug-vna-318","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/en\/vandria-begins-clinical-trials-for-alzheimers-drug-vna-318\/","title":{"rendered":"Vandria begins clinical trials for Alzheimer\u2019s drug VNA-318"},"content":{"rendered":"\n<p><a href=\"https:\/\/vandria.com\/\">Vandria<\/a>, headquartered in Lausanne (canton of Vaud), has initiated its first-in-human clinical trial for VNA-318, an innovative small molecule designed to induce mitophagy, rejuvenate cells, and address neurodegenerative disorders. This milestone brings the company into the clinical stage of development, with Phase 1 trial results anticipated by summer 2025.<\/p>\n\n\n\n<p>VNA-318, an orally available drug, targets novel pathways linked to conditions such as Alzheimer\u2019s disease. The compound offers a dual mode of action, providing immediate cognitive improvements and long-term benefits, including reduced neuroinflammation, decreased toxic protein aggregation, and enhanced mitochondrial function. These effects have been demonstrated in preclinical models of Alzheimer\u2019s and Parkinson\u2019s disease. Toxicity studies have shown the compound to be safe, with a wide therapeutic window, and it is protected under a US-issued patent.<\/p>\n\n\n\n<p>The randomized, double-blind Phase 1 trial evaluates single and multiple ascending doses of VNA-318 in healthy male participants. It aims to assess safety, tolerability, pharmacokinetics, and pharmacodynamics. The drug is initially being developed for early-stage CNS disorders and neurodegenerative diseases, with a focus on improving memory and slowing cognitive decline.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Phase 1 trial and future plans<\/h4>\n\n\n\n<p>In the company\u2019s press release, Vandria CEO Klaus Dugi emphasized the significance of this step: \u201cWe believe VNA-318 has the potential to address critical unmet medical needs in Alzheimer\u2019s and other CNS conditions, bringing hope to patients and their families.\u201d<\/p>\n\n\n\n<p>Backed by a USD 32 million Series A funding round, Vandria plans to advance VNA-318 into efficacy-focused Phase 1b\/2a trials by early 2026 while progressing its broader pipeline addressing muscle, lung, and liver diseases. The company intends to raise additional Series B funding in 2025 to support Phase 2 trials and its expanding therapeutic portfolio.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Vandria, a Lausanne-based biotech pioneer in mitochondrial therapeutics, has dosed the first participants in a Phase 1 clinical trial for its lead compound, VNA-318, marking a critical step toward addressing neurodegenerative diseases such as Alzheimer\u2019s and Parkinson\u2019s.<\/p>\n","protected":false},"author":6,"featured_media":29961,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[833],"tags":[912,894,890,902,886,901],"class_list":["post-29903","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-life-science","tag-biotech","tag-financing","tag-healthcare","tag-personalized-medicine","tag-rd","tag-technology-park"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Vandria begins clinical trials for Alzheimer\u2019s drug VNA-318 | GGBa<\/title>\n<meta name=\"description\" content=\"Vandria, a pioneer in mitochondrial therapeutics, has dosed the first participants in a Phase 1 clinical trial for its lead compound, VNA-318.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/en\/vandria-begins-clinical-trials-for-alzheimers-drug-vna-318\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vandria begins clinical trials for Alzheimer\u2019s drug VNA-318 | GGBa\" \/>\n<meta property=\"og:description\" content=\"Vandria, a pioneer in mitochondrial therapeutics, has dosed the first participants in a Phase 1 clinical trial for its lead compound, VNA-318.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/en\/vandria-begins-clinical-trials-for-alzheimers-drug-vna-318\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-07T09:18:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-08T13:06:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2025\/01\/Vanarix-Cartibeads-1180x811-v3.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/en\/vandria-begins-clinical-trials-for-alzheimers-drug-vna-318\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/en\/vandria-begins-clinical-trials-for-alzheimers-drug-vna-318\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Vandria begins clinical trials for Alzheimer\u2019s drug VNA-318\",\"datePublished\":\"2025-01-07T09:18:29+00:00\",\"dateModified\":\"2025-01-08T13:06:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/vandria-begins-clinical-trials-for-alzheimers-drug-vna-318\/\"},\"wordCount\":283,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/vandria-begins-clinical-trials-for-alzheimers-drug-vna-318\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/01\/Vanarix-Cartibeads-1180x811-v3.png\",\"keywords\":[\"Biotech\",\"Financing\",\"Healthcare\",\"Personalized Medicine\",\"R&amp;D\",\"Technology Park\"],\"articleSection\":[\"Life sciences\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/en\/vandria-begins-clinical-trials-for-alzheimers-drug-vna-318\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/en\/vandria-begins-clinical-trials-for-alzheimers-drug-vna-318\/\",\"url\":\"https:\/\/ggba.swiss\/en\/vandria-begins-clinical-trials-for-alzheimers-drug-vna-318\/\",\"name\":\"Vandria begins clinical trials for Alzheimer\u2019s drug VNA-318 | GGBa\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/vandria-begins-clinical-trials-for-alzheimers-drug-vna-318\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/vandria-begins-clinical-trials-for-alzheimers-drug-vna-318\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/01\/Vanarix-Cartibeads-1180x811-v3.png\",\"datePublished\":\"2025-01-07T09:18:29+00:00\",\"dateModified\":\"2025-01-08T13:06:51+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Vandria, a pioneer in mitochondrial therapeutics, has dosed the first participants in a Phase 1 clinical trial for its lead compound, VNA-318.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/en\/vandria-begins-clinical-trials-for-alzheimers-drug-vna-318\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/en\/vandria-begins-clinical-trials-for-alzheimers-drug-vna-318\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ggba.swiss\/en\/vandria-begins-clinical-trials-for-alzheimers-drug-vna-318\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/01\/Vanarix-Cartibeads-1180x811-v3.png\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/01\/Vanarix-Cartibeads-1180x811-v3.png\",\"width\":1180,\"height\":811,\"caption\":\"The Vandria team, based at the EPFL Innovation Park in Lausanne, is driving innovation in mitochondrial therapeutics, advancing treatments for neurodegenerative and age-related diseases. | \u00a9 Vandria\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/en\/vandria-begins-clinical-trials-for-alzheimers-drug-vna-318\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vandria begins clinical trials for Alzheimer\u2019s drug VNA-318\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vandria begins clinical trials for Alzheimer\u2019s drug VNA-318 | GGBa","description":"Vandria, a pioneer in mitochondrial therapeutics, has dosed the first participants in a Phase 1 clinical trial for its lead compound, VNA-318.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/en\/vandria-begins-clinical-trials-for-alzheimers-drug-vna-318\/","og_locale":"en_US","og_type":"article","og_title":"Vandria begins clinical trials for Alzheimer\u2019s drug VNA-318 | GGBa","og_description":"Vandria, a pioneer in mitochondrial therapeutics, has dosed the first participants in a Phase 1 clinical trial for its lead compound, VNA-318.","og_url":"https:\/\/ggba.swiss\/en\/vandria-begins-clinical-trials-for-alzheimers-drug-vna-318\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2025-01-07T09:18:29+00:00","article_modified_time":"2025-01-08T13:06:51+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/01\/Vanarix-Cartibeads-1180x811-v3.png","type":"image\/png"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pierre-Yves Oehrli","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/en\/vandria-begins-clinical-trials-for-alzheimers-drug-vna-318\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/en\/vandria-begins-clinical-trials-for-alzheimers-drug-vna-318\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Vandria begins clinical trials for Alzheimer\u2019s drug VNA-318","datePublished":"2025-01-07T09:18:29+00:00","dateModified":"2025-01-08T13:06:51+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/en\/vandria-begins-clinical-trials-for-alzheimers-drug-vna-318\/"},"wordCount":283,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/en\/vandria-begins-clinical-trials-for-alzheimers-drug-vna-318\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/01\/Vanarix-Cartibeads-1180x811-v3.png","keywords":["Biotech","Financing","Healthcare","Personalized Medicine","R&amp;D","Technology Park"],"articleSection":["Life sciences"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/en\/vandria-begins-clinical-trials-for-alzheimers-drug-vna-318\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/en\/vandria-begins-clinical-trials-for-alzheimers-drug-vna-318\/","url":"https:\/\/ggba.swiss\/en\/vandria-begins-clinical-trials-for-alzheimers-drug-vna-318\/","name":"Vandria begins clinical trials for Alzheimer\u2019s drug VNA-318 | GGBa","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/en\/vandria-begins-clinical-trials-for-alzheimers-drug-vna-318\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/en\/vandria-begins-clinical-trials-for-alzheimers-drug-vna-318\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/01\/Vanarix-Cartibeads-1180x811-v3.png","datePublished":"2025-01-07T09:18:29+00:00","dateModified":"2025-01-08T13:06:51+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Vandria, a pioneer in mitochondrial therapeutics, has dosed the first participants in a Phase 1 clinical trial for its lead compound, VNA-318.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/en\/vandria-begins-clinical-trials-for-alzheimers-drug-vna-318\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/en\/vandria-begins-clinical-trials-for-alzheimers-drug-vna-318\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ggba.swiss\/en\/vandria-begins-clinical-trials-for-alzheimers-drug-vna-318\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/01\/Vanarix-Cartibeads-1180x811-v3.png","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/01\/Vanarix-Cartibeads-1180x811-v3.png","width":1180,"height":811,"caption":"The Vandria team, based at the EPFL Innovation Park in Lausanne, is driving innovation in mitochondrial therapeutics, advancing treatments for neurodegenerative and age-related diseases. | \u00a9 Vandria"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/en\/vandria-begins-clinical-trials-for-alzheimers-drug-vna-318\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/en\/"},{"@type":"ListItem","position":2,"name":"Vandria begins clinical trials for Alzheimer\u2019s drug VNA-318"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/29903","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/comments?post=29903"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/29903\/revisions"}],"predecessor-version":[{"id":29907,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/29903\/revisions\/29907"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media\/29961"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media?parent=29903"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/categories?post=29903"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/tags?post=29903"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}